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Properties of the late erythrocytic progenitor cells (CFU-E) 1 (1, 2) and of the earlier 
erythropoietic  progenitor  cells  (BFU-E)  (3)  have  largely  been  deduced  from  the 
behavior of their differentiated progeny in erythrocytic colonies or bursts, rather than 
from  direct  studies  on  the  progenitor  cells  themselves.  Because  changes  in  the 
expression  of cell  surface  molecules  are  known  to  occur  along  the  differentiation 
pathways of several cell types (4,  5), we used an immunological approach to try to 
identify cell surface molecules characteristic of particular stages of differentiation in 
the erythrocytic lineage of mice. Such markers, if found, should make it possible to do 
direct studies on these progenitor cells. 
A  scheme of reciprocal  immunization  was  chosen  to  exploit  the  limited  genetic 
difference between the congenic mouse strains C57BL/6Ut  (B6)  and B6.S/Ut  (B6.S). 
The B6.S mouse strain had been made congenic with the B6 inbred strain (6) for the 
purpose of studying the genetic control of the host response to the erythroleukemia- 
inducing  Friend  virus  (7).  The  genetic  difference  between  B6  and  B6.S  was  later 
mapped (8)  to the same segment of chromosome 9 as the Fv-2 gene locus, the major 
determinant  of susceptibility or resistance  to this  virus  (9).  The  B6.S  mouse strain 
carrying the Fv-28 allele is susceptible, whereas the B6 mouse strain, with the Fv-2" 
allele, is resistant to Friend virus. 
Recently (10)  it was discovered that the Fv-2 locus functions in uninfected animals 
as  well,  where  it  controls  the  proportion  of erythropoietic  progenitor  cells  BFU-E 
normally  synthesizing  DNA.  The  Fv-2 ~ allele  in  B6.S  is  associated  with  a  high 
proportion of BFU-E in DNA synthesis, and the Fv-2" allele in B6 mice with a  low 
proportion  of BFU-E  synthesizing DNA.  The findings  of Suzuki  and Axelrad  (10) 
established  that  Fv-2  or  a  closely  linked  gene  had  a  significant  influence  on  cell 
proliferation at a  particular stage in erythrocytic differentiation.  Thus it was hoped 
that  our  strategy  of congenic  immunization  would  generate  a  limited  number  of 
antibodies,  among which  might  be found  antibody directed  against  the  Fv-2  gene 
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1  Abbreviations used in this paper: BFU-E, early erythropoietic progenitor cell; C, complement; CFU-E, late 
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products or against putative erythrocytic differentiation antigens coded for by genes 
closely linked to Fv-2. 
Our efforts have resulted in the production of two unique antisera, a  B6-anti-B6.S 
and a  B6.S-anti-B6 serum, Each antiserum reacts against antigen on the late eryth- 
rocytic progenitor cells CFU-E from the opposite mouse strain. These antigens, which 
were found to be washable from the surface of the CFU-E, were not detected on the 
earlier erythropoietic progenitor cells BFU-E. 
Materials and Methods 
Mice.  B6.S strain mice (Fv-28.) were produced by crosses between C57BL/6J Ut (Fv-2rr) - 
and  SIM/Ut  (Fv-2 Ss)  strain  mice,  followed  by  serial  intercrosses  and  backcrosses  to  the 
C57BL/6  strain with  selection for  susceptibility to  Friend erythroleukemia virus; they  are 
congenic with C57BL/6 strain mice (6, 8).  B6.S and B6 mice were  bred and maintained in 
colonies of the  Division of Laboratory Animal Science,  University of Toronto.  In  all  our 
experiments 8-12-wk-old female mice were used. 
Immunization  Schedule.  Two  immunization schedules were  used.  In one  protocol,  l0  B6 
females ~8 wk old were injected with unwashed B6.S bone marrow and spleen cells;  in the 
other, 10 8-wk-old B6.S females were injected with similar doses of unwashed B6 bone marrow 
and spleen cells. A constant dose of antigen, consisting of 1.0 ×  107 unwashed bone marrow 
and spleen cells in a ratio of 10:1, was administered per host intraperitoneally  or subcutaneously, 
as required. Cells to be used as antigen were collected in phosphate-buffered saline (PBS) and 
pooled to give the appropriate concentration of antigen per injection. 
The immunization  schedule was identical in both directions. The first injection consisted of 
a 0.2 ml vol of antigen in a  1:1 ratio with complete Freund's adjuvant (Gibco Laboratories, 
Grand Island Biological  Co.,  Grand Island, NY) administered intraperitoneally. The second 
injection, given 7 d later, consisted of a 0.2-ml dose of antigen in a  1:1 ratio with incomplete 
Freund's adjuvant (Gibco Laboratories), also  administered intraperitoneally. All further im- 
munizations were performed using a 0.6-ml dose of antigen suspended in PBS administered at 
four subcutaneous sites. Mice were bled 7 d after the fourth injection, and blood was pooled for 
each group of animals. Thereafter, we continued a schedule in which the mice were immunized 
1 wk before blood was collected. This protocol lasted ~ 18 mo. 
Serum Collection.  Blood was collected initially  via orbital bleeding with a pasteur pipette and 
later via tail bleedings. For each group of bleeds we pooled the blood in a  10-ml plastic tube 
(Falcon Labware, Oxnard, CA), then allowed the blood to clot at room temperature for 2 h. 
The clot was removed by low speed centrifugation after retraction overnight at 4°C. Following 
this the serum was diluted 1:1 with minimal essential alpha medium (University of Toronto) 
and passed  through a 0.45-#m millipore filter.  Aliquots of this serum were stored at  -20°C 
until use. 
Antiserum  Treatment  of Cells.  Bone marrow or spleen cells were collected in alpha medium. 
Cells were centrifuged at 160 g for 10 min and resuspended in an aliquot of cold alpha medium 
(washed  cells) or in the original collection medium (unwashed cells). Bone marrow cells were 
suspended to give a final concentration of 107 cells per ml and 0.5 ml of this suspension (5 ×  106 
cells)  was  incubated in  the  presence  of 0.25  ml  antiserum and  0.25  ml  Low-Tox  rabbit 
complement (C)  (Cedarlane Laboratories, Ontario), in a  10-ml  sterile Falcon plastic tube. 
Spleen cells were diluted to give a concentration of 2 ×  107 cells/ml and 0.5 ml of this suspension 
was incubated with 0.25 ml antiserum and 0.25 ml complement. All dilutions were performed 
with cold alpha medium. Tubes were shaken and placed on ice for 30 min and at 37°C for 20 
min. During this incubation the tubes were shaken frequently. At the end of incubation the 
cells  were  washed  with  5  vol  of cold  alpha medium and resuspended in  1.0  ml of Hanks' 
supplemented medium (2). 
CellAssays.  The plasma culture medium used for the assay of CFU-E has been described by 
McLeod et al.  (2) and for BFU-E by McLeod et al. (11). VAITHILINGAM  AND  AXELRAD 
TABLE  I 
The Effect of B6 Anti-B6.S Mouse Serum on  Washed and Unwashed B6.S 
Bone Marrow and Spleen Erythrocytic Progenitor Cells CFU-E 
Mean number 
of erytbrocytic 
colonies "4- S.E.  Percent 
per 5 ×  104  inhibition 
bone marrow  +  S.E. 
cells or per 105 
spleen cells 
Bone marrow 
Washed cells 
Normal B6 serum (1:8)  +  C  (1:8) 
B6.S anti-B6 serum (1:8)  +  C  (1:8) 
B6 anti-B6.S serum (1:8)  +  C  (1:8) 
Unwashed cells 
Normal B6 serum (1:8)  +  C  (1:8) 
B6.S anti-B6 serum (1:8)  +  C  (1:8) 
B6 anti-B6.S serum (1:8)  +  C  (1:8) 
Spleen 
Washed cells 
Normal B6 serum (1:8)  +  C  (1:8) 
B6.S anti-B6 serum (1:8)  +  C  (1:8) 
B6 anti-B6.S serum (1:8)  +  C  (1:8) 
Unwashed cells 
Normal B6 serum (1:8)  +  C  (1:8) 
B6.S anti-B6 serum (1:8)  +  C  (1:8) 
B6 anti-B6.S serum (1:8)  +  C  (1:8) 
598.8 _  31.9 
536.0 ::!: 36.7  10.5 _  8.1 
493.3  :1:31.5  17.6 ::tz 7.5 
645.0 :t: 50.5 
602.6 +_. 32.5  6.6 +  9.3 
319.7  +  28.2  50.4  _  9.8 
84.0 -t- 3.9 
78.5 ::tz 4.2  6.5 ::1:6.7 
72.2 +_ 3.6  14.0 ::lz 6.3 
126.8 +  7.5 
131.8 zl: 12.5  0 
69.8 +  3.3  45.0 ::t: 7.0 
5 ×  10  s B6.S bone marrow or 107 B6.S spleen cells, washed or unwashed, were 
incubated with normal B6 serum, B6.S anti-B6 serum, or B6 anti-B6.S serum 
at  a  final  dilution  of  1:8.  Rabbit  C  was  also  added  to  this  mixture  at  a 
concentration of 1:8, final. Cells incubated in alpha medium (not shown) gave 
similar  colony  plating  efficiencies  as  normal  B6  serum  controls.  Percent 
inhibition was calculated as: 
(Mean number of erythrocytic colonies after normal serum treatment) 
-  (Mean number of erythrocytic colonies after antiserum treatment) ] 
Mean numbe--"----""~  0f erythrocytic colonies after normal seru~ treatmen""""'~  /  /  ×  100%. 
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Results 
Effect of Congenic Antibody on Colony Formation  by CFU-E in  Washed and Unwashed Bone 
Marrow and Spleen  Cell Suspensions.  When  B6.S bone  marrow  cells were resuspended  in 
their original  collection  medium  (unwashed),  treated  with  antiserum  (B6-anti-B6.S), 
and  plated  in plasma  culture,  inhibition  of erythrocytic  colony  formation  to  ~50%  of 
control  was observed  (Table  I).  In contrast,  treatment  of washed  B6.S bone  marrow 
cells with the same serum  resulted in only a  minor  reduction  in number  of erythrocytic 
colonies.  Exposure  of either  washed  or  unwashed  cells to  normal  B6  serum  did  not 
significantly  inhibit  erythrocytic  colony  formation  by  CFU-E  in  the  same  bone 
marrow  cell  suspensions  as  compared  to  alpha  medium  controls  (data  not  shown). 
Antiserum  raised  in B6.S  mice against  unwashed  bone  marrow  and  spleen cells from 
the  B6  congenic  mouse  strain  gave  an  insignificant  reduction  in  the  number  of 
erythrocytic  colonies produced  by washed  B6.S  bone  marrow  cells. This  observation 
was unaltered  when  unwashed  B6.S cells were used. 1494  LATE  ERYTHROCYTIC  PROGENITOR  DIFFERENTIATION  ANTIGENS 
TABLE  II 
The Effect of B6.S Anti-B6 Mouse Serum on  Washed and Unwashed B6 
Bone Marrow and Spleen Erythrocytic Progenitor Cells CFU-E 
Mean number 
of erythrocytic 
colonies  +  S.E.  Percent 
per 5 ×  10  4  inhibition 
bone marrow  ::1: S.E. 
cells or per 10  5 
spleen cells 
Bone marrow 
Washed cells 
Normal B6.S serum (1:8) +  C (1:8)  511.0 ±  21.6  -- 
B6 anti-B6.S serum (1:8) +  C  (1:8)  515.5 ±  41.4  0 
B6.S anti-B6 serum (1:8) +  C  (1:8)  409.3 _  37.8  20.6 +  8.9 
Unwashed cells 
Normal B6.S serum (1:8) +  C  (1:8)  467.7 ±  15.1  -- 
B6 anti-B6.S serum (1:8) +  C  (1:8)  603.3 ±  43.5  0 
B6.S anti-B6 serum (1:8) +  C (1:8)  288.0 ±  11.1  52.3 ±  5.7 
Spleen 
Washed cells 
Normal B6.S serum (1:8) +  C  (1:8)  54.8 +  3.9  -- 
B6 anti-B6.S serum (1:8) +  C (1:8)  45.3 ±  2.6  17.3 ±  8.6 
B6.S anti-B6 serum (1:8) +  C (1:8)  47.0:1:5.0  14.2 ±  11.5 
Unwashed cells 
Normal B&S serum (1:8) +  C  (1:8)  52.0 ±  4.5  -- 
B6 anti-B6.S serum (1:8) +  C  (1:8)  59.7 ±  6.8  0 
B6.S anti-B6 serum (1:8) ±  C  (1:8)  22.5 ±  4.0  56.7 ±  12.5 
5  ×  l0  s  bone  marrow  or  10  7  B6  spleen  cells,  washed  or  unwashed,  were 
incubated with normal B6.S serum, B6-anti-B6.S serum, or B6.S-anti-B6 serum 
at  a  final dilution of  1:8. Rabbit  C  was  also  added  to  this  mixture at  a 
concentration of 1:8, final. Cells incubated in alpha medium (not shown) gave 
similar  colony-plating efficiencies  as  normal  B6.S  serum  controls.  Percent 
inhibition was calculated by the formula shown in Table I. 
The  action of B6 anti-B6.S serum on erythrocytic colony formation  by B6.S spleen 
cells was also studied. We found that exposure of B6.S spleen cells to normal  B6 serum 
did  not  reduce  the  erythrocytic  colony-forming  efficiency  of  the  washed  or  the 
unwashed  spleen cells when  compared  to alpha  medium  controls  (data  not  shown). 
Similarly,  treatment  of washed  or  unwashed  B6.S  spleen  cells  with  B6.S  anti-B6 
serum  showed  no  effect  on  erythrocytic  colony  formation  by  their progenitor  cells. 
However,  the B6  anti-B6.S  serum  produced  a  45%  inhibition  of erythrocytic  colony 
formation  by  unwashed  spleen  cells,  but  only  an  insignificant  14%  reduction  on 
washed cells from B6.S spleen. 
We  next  used the same  approach  to determine  the activity of B6.S-anti-B6 serum 
against erythroid  progenitor  cells from  the B6 strain.  Normal  serum  from  B6.S  mice 
did not affect erythrocytic colony formation by washed or unwashed  B6 bone marrow 
or  spleen  cells,  as  compared  to  alpha  medium  controls  (data  not  shown).  In  no 
instance  did  the  B6-anti-B6.S  serum  influence  erythrocytic  colony  formation  by 
washed or unwashed  B6 bone marrow  or spleen cells. Only a  minor  inhibition by this 
antiserum  of colony formation  by washed  spleen cells was observed  (Table II). 
When  unwashed  B6 bone  marrow  and  spleen  cells were  incubated  with  the B6.S- VAITHILINGAM AND AXELRAD 
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Fio.  1.  Titration curve of the B6 anti-B6.S mouse serum inhibition oferythrocytic  colony formation 
by CFU-E (  ) and erythropoietic  burst formation  by BFU-E  (-- -- --) of unwashed  B6.S 
bone marrow. 5 ×  10  6 cells were exposed to serial dilutions of the antibody, and aliquots of the cells 
were seeded, after washing, in plasma culture medium. The B6.S-anti-B6 serum control and alpha 
medium control gave plating efficiencies similar to those of the normal B6 serum control. Percent 
inhibition was calculated by the formula shown in Table I. 
anti-B6 serum  before seeding in  plasma cultures, erythrocytic colony formation  by 
bone  marrow  cells was  reduced  by 52%,  and  by spleen  cells by  57%.  Only a  21% 
inhibition  of erythrocytic  colony  formation  was  observed  when  washed  B6  bone 
marrow cells and a  14% inhibition when washed spleen cells were incubated with the 
same antiserum. 
A  titration of B6-anti-B6.S mouse serum was  performed on  unwashed  B6.S  bone 
marrow progenitors. Fig.  I  shows that a  maximum  inhibition of erythrocytic colony 
formation by CFU-E was observed at a  serum dilution of 1:40. Activity in the serum 
against the colony-forming cells diminished rapidly between dilutions 1:80 and 1:160. 
No significant inhibition of erythropoietic burst  formation by BFU-E was observed 
by  this  same  antiserum  at  any  of  the  dilutions  tested  with  the  exception  of  a 
questionable effect at a  1:40 dilution. 
When B6.S-anti-B6 serum was titrated on unwashed B6 bone marrow cells (Fig. 2), 
maximal  inhibition  of erythrocytic  colony  formation  was  observed  up  to  a  1:40 
dilution  of the  antiserum.  In  subsequent  dilutions,  antibody  activity  diminished 
rapidly.  This  antiserum  did  not  affect  the  formation  of erythropoietic  bursts  by 
BFU-E. 
Effect of Congenic Antibody on Burst Formation by BFU-E in  Washed and Unwashed Bone 
Marrow and Spleen Cell Suspensions. Because the proliferative status of the BFU-E differs 
between the B6 and  B6.S mouse strains  (10), we decided to examine in more detail 
the effect of our antisera, raised between these congenic strains, on the burst-forming 
activity of BFU-E found in the bone marrow and spleens of these animals. 1496  LATE  ERYTHROCYTIC  PROGENITOR  DIFFERENTIATION  ANTIGENS 
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FIG. 2.  Titration curve of the B6.S anti-B6 mouse  serum inhibition oferythrocytic colony  formation 
by CFU-E (  ) and erythropoietic burst formation by BFU-E (-- -- --) of unwashed B6 bone 
marrow. 5 ×  106 cells were exposed to serial dilutions of the antibody, and aliquots of these cells 
were seeded, after washing, in plasma culture medium. The B6 anti-B6.S serum control and alpha 
medium control gave plating efficiencies  similar to those of the normal B6.S serum control. Percent 
inhibition was calculated by the formula shown in Table I. 
The  data  presented  in Tables III and IV show  the  results of these  experiments. 
Bone  marrow  and  spleen  BFU-E  obtained  from  B6.S  mice  were  unaffected  by 
exposure  to  normal B6 serum as  compared with alpha medium controls  (data  not 
shown).  Insignificant reductions  in  burst  formation  were  found  when  washed  or 
unwashed B6.S  bone marrow or spleen cells were treated with  B6.S  anti-B6 serum 
(Table III). Unlike the observations recorded on the reduction in number of eryth- 
rocytic colonies formed by CFU-E as a consequence of B6-anti-B6.S serum treatment, 
the same serum failed to produce a  significant reduction in the number of erythro- 
poietic bursts produced by BFU-E among B6.S washed or unwashed bone marrow or 
spleen cells (Table III). 
We next attempted  to  assay the  B6.S  anti-B6 serum  for activity against BFU-E 
from the B6 mouse strain. Results obtained in this series of experiments (Table IV) 
were again negative, similar to those obtained previously on B6.S erythropoietic burst 
formation with the  anti-B6.S serum.  Exposure of B6  bone marrow cells to  normal 
B6.S  serum  did  not  affect  the  burst-forming efficiency of these  progenitor cells as 
compared to alpha medium controls (data not shown). Also, the control B6-anti-B6.S 
serum gave an insignificant inhibition of burst formation by washed B6 bone marrow 
cells. The B6.S-anti-B6 serum also produced a  17% inhibition of burst formation by 
the erythro~,oietic progenitor cells which, however, did not reach the level of statistical 
significance. No significant inhibition of erythropoietic burst formation by B6.S-anti- 
B6 serum treatment of washed or unwashed B6 spleen cells was observed. 
Thus, CFU-E but not BFU-E appeared to be susceptible to inhibition by antisera VAITttILINGAM  AND  AXELRAD  1497 
TABLE  III 
The Effect of B6 Anti-B6.S Mouse Serum on  Washed and Unwashed B6.S 
Bone Marrow and Spleen E~ythropoietic Progenitor Cells BFU-E 
Mean number 
of erythropoi-  Percent 
etic bursts d- 
inhibition 
S.E. per 10  ~  d- S.E. 
bone marrow 
or spleen cells 
Bone marrow 
Washed cells 
Normal B6 serum (1:8)  +  C  (1:8)  44.7 d. 3.6  -- 
B6.S anti-B6 serum  (1:8)  +  C  (1:8)  42.2 +  2.0  5.6 d. 9.2 
B6 anti-B6.S serum  (1:8)  +  C  (1:8)  47.0 d. 2.2  0 
Unwashed cells 
Normal B6 serum (1:8)  +  C  (1:8)  44.2 d. 2.5  -- 
B6.S anti-B6 serum (1:8)  +  C  (1:8)  47.0 +  3.1  0 
B6 anti-B6.S serum (1:8)  +  C  (1:8)  44.0 d. 2.1  0.5 d. 8.1 
Spleen 
Washed cells 
Normal B6 serum  (1:8) +  C  (1:8)  8.7 "4- 1.0  -- 
B6.S anti-B6 serum (1:8)  +  C  (1:8)  8.2 d. 0.7  5.7 d.  14,8 
B6 anti-B6.S serum (1:8) +  C  (1:8)  7.8 d. 0.5  10.3 "4-  12.8 
Unwashed cells 
Normal B6 serum (1:8) +  C  (1:8)  10.5 ±  1,6  -- 
B6.S anti-B6 serum (1:8) +  C  (1:8)  9,8 ±  1.5  6.7 ±  21.0 
B6 anti-B6.S serum (1:8) +  C  (1:8)  8.8 -I- 0.3  16,2 ±  t5.7 
5  ×  10  s  bone  marrow  or  l0  T B6.S  spleen  cells, washed  or  unwashed,  were 
incubated with normal B6 serum, B6.S-anti-B6 serum, or B6-anti-B6.S serum 
at  a  final  dilution  of  1:8.  Rabbit  C  was  also  added  to  this  mixture  at  a 
concentration of 1:8, final. Cells incubated in alpha medium (not shown) gave 
similar burst-plating efficiencies as normal B6 controls. Percent inhibition was 
calculated by the formula shown in Table I. 
produced  in  the  congenic  partner  strains.  Washing  of these  cells  rendered  them 
insusceptible to the inhibitory action of the antisera. 
Discussion 
The  data  presented  in  this  study  are  consistent  with  the  hypothesis  that  our 
congenic anti-B6.S  and  anti-B6 antisera define erythrocytic differentiation antigens 
at the surface of the late erythrocytic progenitor cells, CFU-E. A reduction of ~50% 
in  number  of erythrocytic  colonies  arising  from  marrow  and  spleen  CFU-E  was 
produced  by  both  antisera.  In  none  of  the  experiments  did  we  demonstrate  a 
significant  antiserum-induced  reduction  in  number of erythropoietic bursts  formed 
by BFU-E.  The antisera were specific since normal sera had  no effect, and neither 
antiserum  reacted  against  CFU-E  obtained  from  the  mouse  strain  in  which  the 
particular antiserum was generated. 
A  simple  explanation  for  the  failure  of our  antisera  to  show  interaction  with 
BFU-E would be that the BFU-E does not possess the antigenic material at the cell 
surface  that  binds  these antibodies,  and  thus  CFU-E  and  BFU-E  are qualitatively 
different. Alternatively, the BFU-E may possess the same surface antigenic determi- 
nants  but  in  low concentration.  The plasma culture  burst-inhibition  assay method 1498  LATE  ERYTHROCYTIC  PROGENITOR  DIFFERENTIATION  ANTIGENS 
TABLE  IV 
The Effect of B6.S Anti-B6 Mouse Serum on  Washed and Unwashed B6 
Bone Marrow and Spleen Erythropoietic Progenitor Cells BFU-E 
Mean number 
of erythropoi-  Percent 
etic bursts :i:  inhibition 
S.E. per 10  ~  2: S.E. 
bone marrow 
or spleen cells 
Bone marrow 
Washed cells 
Normal B6.S serum (1:8) +  C  (1:8)  35.8 -I- 2.4  -- 
B6 anti-B6.S serum (1:8) +  C  (1:8)  31.8 2:1.2  11.l 2:7.4 
B6.S anti-B6 serum (1:8) +  C  (1:8)  29.8 +  2.8  16.8 2:10.3 
Unwashed cells 
Normal B6.S serum (1:8) +  C  (1:8)  31.3 2:2.6  -- 
B6 anti-B6.S serum (1:8) +  C  (1:8)  32.8 2:1.6  0 
B6.S anti-B6 serum (1:8) +  C  (1:8)  29.5 +  3.4  5.8 2:13.8 
Spleen 
Washed cells 
Normal B6.S serum (1:8) +  C (1:8)  11.8 +  1.7  -- 
B6 anti-B6.S serum (1:8) +  C (1:8)  12.7 +  0.6  0 
B6.S anti-B6 serum (1:8) +  C  (1:8)  9.5 +  0.8  19.5 +  15.9 
Unwashed cells 
Normal B6.S serum (1:8) +  C (1:8)  10.2 2:0.9  -- 
B6 anti-B6.S serum (1:8) +  C  (1:8)  11.2 -e 0.9  0 
B6.S anti-B6 serum (1:8) +  C (1:8)  12.2 +  1.5  0 
5  X  10  6 B6 bone marrow or  107 B6 spleen cells, washed or unwashed were 
incubated with normal B6.S serum, B6-anti-B6.S serum, or B6.S-anti-B6 serum 
at  a  final dilution of  1:8. Rabbit  C  was  also  added  to  this mixture at  a 
concentration of 1:8, final. Cells incubated in alpha medium (not shown) gave 
similar plating efficiencies  as normal B6.S serum controls. Percent inhibition 
was calculated by the formula shown in Table I. 
thus may simply be too insensitive to detect the antigens on BFU-E. This would imply 
a  quantitative  difference between CFU-E  and BFU-E  with respect to these cell surface 
antigenic  determinants.  Whether  the difference  turns out  to  be qualitative  or quan- 
titative,  it  is  clear  that  expression  of the  antigenic  determinants  on  the  surface  of 
erythropoietic  progenitor  cells  varies  with  the  stage  of  differentiation  along  the 
erythrocytic lineage. 
Washing  or  not  washing  of the  bone  marrow  or  spleen  cells  was  critical  to  the 
detection  of antibody  action  against  CFU-E.  Among  bone  marrow  or  spleen  cells 
collected  in  alpha  medium,  centrifuged,  and  resuspended  in  fresh  alpha  medium 
(washed),  the  CFU-E  were  unaffected  by  either  antibody.  However,  when  such 
washed  bone marrow  or spleen cells were resuspended  in supernatants  obtained  from 
the same centrifuged bone marrow  or spleen cells (unwashed), the CFU-E  were found 
to be strongly inhibited by both antibodies. On  this basis, we have postulated  that the 
antigenic  determinants  recognized  by  both  antisera  are  associated  with  the  cell 
surface,  and  the fact  that  these antigens appear  to dissociate from the cell surface as 
a  result  of  simply  washing  with  alpha  medium  implies  that  they  are  not  firmly 
anchored  in the cell membrane  of the CFU-E.  Moreover, the fact that the CFU-E  can 
be rendered vulnerable  to the antibodies by exposure to the supernatant  suggests that VAITHILINGAM AND AXELRAD  1499 
an entity bearing the antigenic determinants and present in these supernatants  can 
become adsorbed to the surface of the CFU-E. It is not known whether erythrocytic 
colony inhibition after treatment of bone marrow and spleen cells with anti-B6 and 
anti-B6.S antisera occurred via a  cytotoxic mechanism. The plasma culture system 
contains minor amounts of complement, hence antibody dependence on complement 
could not be assessed.  Culture media free of complement will be required to resolve 
this problem. 
The maximal inhibitory effect of 50% by our antisera is unexplained. Perhaps this 
indicates the existence of subpopulations within the CFU-E compartment (13,  14), or 
alternatively, the antigenic molecules may only interact with progenitor cells during 
a particular phase of their cell cycle (15). This possibility postulates the appearance, 
only during a specific phase of the cell cycle, of surface receptors that would render 
the  cell  susceptible  to  regulation  by  factor(s)  binding  to  such  receptors.  Either 
explanation would account for the 50% inhibition by the congenic antisera of CFU-E 
present in bone marrow and spleen tissues. 
The two congenic antibodies behaved identically against the CFU-E from mice of 
the opposite Fv-2 genotype. However, it is still unclear whether the antigenic deter- 
minants detected by these antisera are coded for by alleles at  the Fv-2 locus or by 
different genes closely linked on the segment of chromosome 9 by which the B6 and 
B6.S strains  differ. To our knowledge, there are no precedents in the literature for 
erythrocytic antigens coded for by genes in this chromosome segment. Experiments 
are  in  progress to examine these possibilities,  and  we  are currently completing an 
analysis of antibodies produced by hybridomas constructed from mice used to raise 
the two antisera described here. 
Overall, the results obtained indicate that novel erythrocytic differentiation anti- 
gens at the CFU-E level have been identified by the antisera we have produced. Both 
antisera display immunologic, genetic, and cellular specificity, but functions of the 
antigens they recognize are unknown. A number of studies (16,  17) have shown that 
shed cell surface molecules may function as regulators of growth and differentiation 
in a variety of experimental systems. It is thus possible that the B6 and B6.S antigens 
detected  in  this  study  may  also  function  as  regulators,  in  this  case  along  the 
erythrocytic lineage. This possibility is presently under investigation in our laboratory. 
Summary 
We have investigated the activities of alloantisera produced in B6 (C57BL/6) and 
B6.S strain mice reciprocally immunized with unwashed bone marrow and spleen cell 
suspensions from their respective Fv-2 congenic partner strains, B6.S and B6. These 
antisera  inhibited  the  formation  of colonies  by  the  late  erythrocytic progenitors 
(CFU-E)  in  plasma  cultures  seeded  with  unwashed  bone  marrow  or spleen  cells; 
washed cells were unaffected. Erythropoietic burst formation by the early progenitors 
(BFU-E) was not significantly inhibited by the antisera, whether the cells were washed 
or unwashed. We conclude (a) that the congenic antisera are capable of recognizing 
alloantigens controlled by alleles of Fv-2 or of a closely linked gene locus on chromo- 
some 9; (b) that these alloantigens are situated on the surface oferythrocytic progenitor 
cells and can be removed by washing; and (c) that the expression of the alloantigens 
on these cells is influenced by their stage of differentiation. 
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